Background: Imatinib, a tyrosine kinase inhibitor, causes growth failure in children with chronic myeloid leukemia probably by targeting the growth hormone (GH)/insulin like growth factor-1 (IGF-1) axis. This evidence concerns the gene GH1 and chronic myelogenous leukemia, BCR-ABL1 positive.